2 min read

Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders

Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders

Organization recognizes the most promising and innovative health startups in New York.

New York, February 2, 2022 -- Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York's healthcare ecosystem, has recognized the company on its NYC Digital Health 100, showcasing the most exciting and innovative health start-ups in New York.

"We are thrilled to be recognized on NYCHBL's Digital Health 100 among a list of impressive startups," said James K. Min, MD FACC, founder and CEO of Cleerly. "We continue to have a strong presence in New York City with our employee footprint, and working with prominent health care systems and research institutions as we strive to transform the way we evaluate heart disease."

Founded in 2017, Cleerly's digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through artificial intelligence (AI)-enabled and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build proprietary algorithms capable of quantifying and characterizing the presence, extent, severity and type of coronary artery disease and other cardiovascular disorders. Through this visibility and understanding of coronary artery disease, Cleerly is transforming the field of cardiovascular medicine by introducing a multidimensional approach to serve each and every stakeholder – from imaging physicians, to clinicians, to patients and payers.

"This year, the NYC Digital Health 100 is comprised of an incredibly diverse set of companies and leaders who are working to innovate and solve some of the most complex challenges across all facets of the healthcare ecosystem," said Bunny Ellerin, co-founder and CEO, NYCHBL. "We are delighted to recognize these companies and celebrate and support their growth in the New York area."

The NYC Digital Health 100 was released in conjunction with the NYCHBL Healthcare Innovation Report 2022, an in-depth look at the data, trends and insights that define the healthcare industry in NY. In 2021, 182 companies raised an historic high of $9.0B, a 150% increase from 2020 ($3.6B) and 87% of the investments went to start-ups in areas including virtual care, patient engagement and mental health. To review the report, please visit https://bit.ly/dh100-pr.

 


 

About Cleerly

Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.

Cleerly Press Contact:

press@cleerlyhealth.com

 


 

Resources
Cleerly Named to NYCHBL Digital Health 100

Download: JPG

 

 

 

View more media resources ⇢

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA

Read More
Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial

Read More
Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

Read More